Chi-square test, p < 0.001. *4/15 patients < 3 mg/dL were on allopurinol combined with benzbromarone; **9/30 patients < 3 mg/dL were on febuxostat combined with benzbromarone.
Declarations
Acknowledgments
To the patients who shared their data through all these years.
Author contributions
FPR: Conceptualization, Investigation, Data curation, Formal analysis, Funding acquisition, Writing—original draft, Writing—review & editing, Visualization. NPH: Data curation, Formal analysis, Writing—original draft, Writing—review & editing, Visualization. Both authors read and approved the submitted version.
Conflicts of interest
FPR is or has been an advisor for Crystalyx, Protalix, and SOBI; speaker for Menarini and Spanish Foundation for Rheumatology. FPR, who is the Editor-in-Chief of Exploration of Musculoskeletal Diseases, had no involvement in the decision-making or the review process of this manuscript. The other author declares no conflicts of interest.
Ethical approval
The study was approved by the Ethics Committee of OSI EEC at Cruces University Hospital (registry number CEIC-E03/45) and complied with the principles of the Declaration of Helsinki.
Consent to participate
Informed consent to participate in the study was obtained from the participants, or their legal guardians if applicable.
Consent to publication
Not applicable.
Availability of data and materials
The datasets for this study can be obtained on request from the first author, if approval is provided by the Ethics Committee.
Funding
This study has been partially funded by Cruces Rheumatology Association (ARC, grant 01/2025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. FPR is a member of ARC, but took no part in funding decisions.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout.Ann Rheum Dis. 2017;76:29–42. [DOI] [PubMed]
Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al.; British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout.Rheumatology (Oxford). 2007;46:1372–4. [DOI] [PubMed]
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout.Arthritis Care Res (Hoboken). 2020;72:744–60. [DOI] [PubMed] [PMC]
Neilson J, Bonnon A, Dickson A, Roddy E; Guideline Committee. Gout: diagnosis and management—summary of NICE guidance.BMJ. 2022;378:o1754. [DOI] [PubMed]
Latourte A, Bardin T, Richette P. Uric acid and cognitive decline: a double-edge sword?Curr Opin Rheumatol. 2018;30:183–7. [DOI] [PubMed]
Latourte A, Soumaré A, Bardin T, Perez-Ruiz F, Debette S, Richette P. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.Ann Rheum Dis. 2018;77:328–35. [DOI] [PubMed]
D’Silva KM, Yokose C, Lu N, McCormick N, Lee H, Zhang Y, et al. Hypouricemia and Mortality Risk in the US General Population.Arthritis Care Res (Hoboken). 2021;73:1171–9. [DOI] [PubMed] [PMC]
Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout.J Rheumatol. 2009;36:1273–82. [DOI] [PubMed]
Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.Ann Rheum Dis. 2013;72:1469–74. [DOI] [PubMed] [PMC]
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure; a cooperative study.JAMA. 1977; 237:255–61. [DOI]
National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [Internet].Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004. [PubMed]
Grundy SM, Bilheimer D, Chait A, Clark LT, Denke M, Havel RJ, et al. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).JAMA. 1993;269:3015–23. [DOI]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001;285:2486–97. [DOI] [PubMed]
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care. 1997;20:1183–97. [DOI] [PubMed]
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care. 2003;26:S5–20. [DOI] [PubMed]
de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.Arthritis Care Res (Hoboken). 2016;68:667–72. [DOI] [PubMed]
Pérez Ruiz F, Richette P, Stack AG, Karra Gurunath R, García de Yébenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.RMD Open. 2019;5:e001015. [DOI] [PubMed] [PMC]
Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.Ann Rheum Dis. 2014;73:177–82. [DOI] [PubMed]
Lv YL, Liu YM, Dong KX, Ma XB, Qian L. Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients.Sci Rep. 2024;14:26675. [DOI] [PubMed] [PMC]
Makinouchi R, Koyama T, Machida S, Imai N. Hypouricemia in the emergency department: A retrospective, single‐center study.Health Sci Rep. 2023;6:e1467. [DOI] [PubMed] [PMC]
Son CN, Kim JM, Kim SH, Cho SK, Choi CB, Sung YK, et al. Prevalence and possible causes of hypouricemia at a tertiary care hospital.Korean J Intern Med. 2016;31:971–6. [DOI] [PubMed] [PMC]
Rahimi-Sakak F, Maroofi M, Rahmani J, Bellissimo N, Hekmatdoost A. Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants.BMC Cardiovasc Disord. 2019;19:218. [DOI] [PubMed] [PMC]
Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. Clinical and Molecular Analysis of Patients with Renal Hypouricemia in Japan-Influence of URAT1 Gene on Urinary Urate Excretion.J Am Soc Nephrol. 2004;15:164–73. [DOI] [PubMed]
Raivio KO, Saksela M, Lapatto R. Xanthine oxidoreductase—role in human pathophysiology and in hereditary xanthinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Online Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill Education; 2001. pp. 2639–52. [DOI]
Crawley WT, Jungels CG, Stenmark KR, Fini MA. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.Redox Biol. 2022;51:102271. [DOI] [PubMed] [PMC]
Hershfield MS. Reassessing serum urate targets in the management of refractory gout: can you go too low?Curr Opin Rheumatol. 2009;21:138–42. [DOI] [PubMed] [PMC]
Kelly B, Gamble GD, Horne A, Doyle AJ, Drake J, Aati O, et al. Relationship between serum urate and changes in dual-energy CT monosodium urate crystal volume over 1 year in people with gout: an individual participant data analysis.Ann Rheum Dis. 2025;84:136–142. [DOI] [PubMed]
Yan Y, Bai Y, Wang J, Li G. Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis.Expert Opin Drug Saf. 2024:1–9. [DOI] [PubMed]
Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment—safety issues, latest evidence and clinical considerations.Ther Adv Drug Saf. 2017;8:379–88. [DOI] [PubMed] [PMC]
Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.Ann Rheum Dis. 1998;57:545–9. [DOI] [PubMed] [PMC]
Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout.Arthritis Care Res (Hoboken). 2002;47:356–60. [DOI] [PubMed]
Calvo-Aranda E, Gómez-González CM, Pérez-Ruiz F, Novella-Navarro M. The ‘FebBenz’ approach for severe difficult-to-treat gout.Explor Musculoskeletal Dis. 2025;3. [DOI]
Browne LD, Jaouimaa FZ, Walsh C, Perez-Ruiz F, Richette P, Burke K, et al. Serum uric acid and mortality thresholds among men and women in the Irish health system: A cohort study.Eur J Intern Med. 2021;84:46–55. [DOI] [PubMed]
Şengüldür E, Demir MC, Selki K. Prevalence and clinical significance of hypouricemia in the emergency department.Medicine (Baltimore). 2024;103:e41105. [DOI] [PubMed] [PMC]
